Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0239946 (
liver fibrosis
)
8,268
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Decoy receptor 3
(
DcR3
) is a tumor necrosis factor receptor, which may inhibit apoptosis. The aim of the present study was to investigate the clinical significance of
DcR3
upregulation in patients with chronic hepatitis B (CHB) and hepatic fibrosis. A total of 128 patients with a clinical diagnosis of CHB who underwent liver biopsy were included in the present study. The expression levels of
DcR3
, hyaluronic acid (HA), type III procollagen, type IV collagen (IV-C) and laminin protein were assessed. The diagnostic value of
DcR3
in patients with CHB with hepatic fibrosis was determined using receiver operating characteristic (ROC) curve analysis.
DcR3
was significantly upregulated in patients with CHB, particularly in patients with active CHB. The expression of
DcR3
was significantly increased in patients with CHB with
liver fibrosis
and liver cirrhosis, compared with patients with CHB without
liver fibrosis
. The area under the ROC curve for the diagnosis of CHB
liver fibrosis
based on
DcR3
or
DcR3
combined with IV-C/HA was 0.807 or 0.869, with a sensitivity and specificity of 76.9 and 77.8% or 84.6 and 81.2%, respectively.
DcR3
is a marker for
liver fibrosis
in patients with hepatitis B infection. The use of
DcR3
in combination with IV-C and HA may further increase its diagnostic value for
liver fibrosis
.
...
PMID:Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis. 3006 40
